These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26863836)

  • 1. Fast track to 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Jan; 70(1):56-62. PubMed ID: 26863836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 4. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintaining qualification for 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Mar; 70(3):70-5. PubMed ID: 27183761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 340B program presents opportunities--and challenges.
    Keough CL; Webster SA
    Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: cost savings.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
    [No Abstract]   [Full Text] [Related]  

  • 14. Built for the road ahead.
    Mansour A
    Healthc Financ Manage; 2015 Oct; 69(10):76-81. PubMed ID: 26595980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing 340B purchasing practices.
    Almeter PJ; Johnson GL; Saenz R
    Am J Health Syst Pharm; 2012 Aug; 69(16):1366-8, 1370-1. PubMed ID: 22855101
    [No Abstract]   [Full Text] [Related]  

  • 16. Using 340B drug discounts to provide a financially sustainable medication discharge service.
    Wu T; Williams C; Vranek K; Mattingly TJ
    Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.
    Castellon YM; Bazargan-Hejazi S; Masatsugu M; Contreras R
    Am J Manag Care; 2014 Feb; 20(2):146-50. PubMed ID: 24738532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
    Health Resources and Services Administration, Department of Health and Human Services (HHS)
    Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan K; Romley JA; Myerson R
    BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.